OmniAb, Inc.
Crystal Nie has extensive work experience in various roles and industries. Crystal currently works as a Lab Operations Sr. Manager at OmniAb, Inc. starting from November 2022. Prior to this, they worked at Ligand Pharmaceuticals as a Sr. Manager Lab Operations from September 2022 to October 2022, and as a Laboratory Operations Manager from November 2021 to August 2022. Crystal also gained valuable experience as an R & D Manager / Analytical Chemist at Valent U.S.A. LLC from May 1997 to November 2021. Additionally, they have volunteered as a Parent Volunteer at ECPC and Madera Elementary School from September 2008 to June 2020. Crystal's earlier experiences include being an Emergency Room Volunteer and Trainer at Children's Hospital Oakland from July 1993 to October 2004, an Associate at USDA, FSIS from October 1995 to May 1997, and a USMC Officer Candidate in the US Marine Corps during June 1994 to July 1994.
Crystal Nie attended UC Berkeley from 1990 to 1995, where they completed their Bachelor of Science in Chemistry.
This person is not in any teams
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.